Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03804996
Title Study of TG-1801 in Subjects With B-Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications

B-cell lymphoma

Therapies

TG-1801 + Ublituximab

TG-1801

Age Groups: adult | senior
Covered Countries

Facility Status City State Zip Country Details
TG Therapeutics Investigational Trial Site Recruiting Heidelberg Victoria 03084 Australia Details
TG Therapeutics Investigational Trial Site Completed Melbourne Victoria Australia Details
TG Therapeutics Investigational Trial Site Recruiting Nedlands Western Australia 06009 Australia Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field